Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in Major Depressive Disorder
NCT01355081Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Takeda. Primary endpoint: Montgomery-Åsberg Depression Rating Scale Total Score at 8 weeks. Started May 2011; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01355081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01355081.